Milgamma (Benfotiamine, Pyridoxine Hydrochloride)

Benfotiamine and Pyridoxine Hydrochloride, the active ingredient in Milgamma, is a Vitamin B1 derivative and Vitamin B6 presented as an oral nutritional supplement for oral use. It supports carbohydrate metabolism and nerve function, and is used in the management of peripheral neuropathy and vitamin B1/B6 deficiency.

GNH USA supplies Milgamma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Milgamma, a combination of benfotiamine and pyridoxine, is used to support nerve health in conditions involving peripheral neuropathy and vitamin deficiencies.

- Diabetic peripheral neuropathy: helps alleviate sensory symptoms and supports nerve metabolism. - Non‑diabetic peripheral neuropathy: contributes to nerve function and reduces discomfort. - Vitamin B1/B6 deficiency: restores adequate levels of thiamine and pyridoxine for normal metabolic processes.

Milgamma may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Skin reactions: mild rash or itching. - Headache: transient headache episodes. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Hypersensitivity: severe allergic reactions including swelling, hives, or breathing difficulty. - Neuropathy worsening: rare exacerbation of nerve symptoms. - Hematologic changes: uncommon blood count abnormalities. - Liver enzyme elevation: rare increase in hepatic transaminases.

When using Milgamma, consider the following precautions to ensure safe and effective therapy.

- Assess deficiency: evaluate vitamin B1/B6 status before initiating therapy. - Monitor neuropathy: observe symptom changes and adjust treatment as needed. - Renal function: use caution in severe renal impairment. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Drug interactions: review concomitant medications that affect vitamin metabolism. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Milgamma can interact with other medicines; awareness of the interaction level helps manage risk.

Major Interactions (Avoid): - Anticonvulsants (e.g., phenobarbital, phenytoin): may increase vitamin B6 metabolism, reducing efficacy. - High‑dose thiamine antagonists: can counteract benfotiamine activity.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may alter vitamin B6 levels, monitor for side effects. - Chemotherapy agents (e.g., cisplatin): potential additive neurotoxicity, observe nerve function. - Alcohol abuse: impairs thiamine utilization, may require dose adjustment.